Goldman Sachs Group Inc. Sells 138,529 Shares of AnaptysBio, Inc. $ANAB

Key Points

• Goldman Sachs Group Inc. reduced its stake in AnaptysBio, Inc. by 33.1%, selling 138,529 shares and holding approximately 0.95% of the company at a value of $5.2 million.
• First Light Asset Management LLC significantly increased its investment in AnaptysBio, growing its stake by 433.3% during the same quarter, acquiring an additional 3.76 million shares.
• AnaptysBio recently reported $22.26 million in revenue for its last quarter, surpassing analyst expectations of $11.55 million, while also announcing earnings per share of ($1.34), beating a consensus estimate of ($1.50).

Goldman Sachs Group Inc. lowered its holdings in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 33.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 280,577 shares of the biotechnology company's stock after selling 138,529 shares during the period. Goldman Sachs Group Inc. owned about 0.95% of AnaptysBio worth $5,216,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in ANAB. First Light Asset Management LLC grew its position in AnaptysBio by 433.3% in the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company's stock worth $86,139,000 after acquiring an additional 3,764,720 shares in the last quarter. Palo Alto Investors LP raised its stake in AnaptysBio by 20.9% during the 1st quarter. Palo Alto Investors LP now owns 1,020,713 shares of the biotechnology company's stock valued at $18,975,000 after purchasing an additional 176,742 shares during the last quarter. Woodline Partners LP raised its stake in AnaptysBio by 63.1% during the 1st quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company's stock valued at $14,705,000 after purchasing an additional 305,950 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of AnaptysBio by 21.5% in the 1st quarter. Victory Capital Management Inc. now owns 406,430 shares of the biotechnology company's stock valued at $7,556,000 after buying an additional 71,980 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in shares of AnaptysBio by 66.4% in the 4th quarter. Two Sigma Investments LP now owns 352,034 shares of the biotechnology company's stock valued at $4,661,000 after buying an additional 140,457 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ANAB shares. Wedbush restated an "outperform" rating and issued a $45.00 price objective on shares of AnaptysBio in a research note on Tuesday. Guggenheim reiterated a "buy" rating and set a $90.00 target price (up previously from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. JPMorgan Chase & Co. increased their target price on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. UBS Group reissued a "neutral" rating and set a $20.00 price objective (up previously from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. Finally, HC Wainwright raised shares of AnaptysBio from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $22.00 to $38.00 in a report on Wednesday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.13.

Insiders Place Their Bets

In related news, Director Hollings Renton sold 20,925 shares of the business's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the transaction, the director directly owned 4,965 shares in the company, valued at approximately $117,025.05. The trade was a 80.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 33.50% of the company's stock.

AnaptysBio Stock Down 1.1%

AnaptysBio stock traded down $0.24 during midday trading on Friday, hitting $20.84. 679,572 shares of the stock were exchanged, compared to its average volume of 502,877. The company has a fifty day simple moving average of $22.58 and a two-hundred day simple moving average of $21.21. AnaptysBio, Inc. has a 52 week low of $12.21 and a 52 week high of $39.12. The stock has a market capitalization of $583.52 million, a PE ratio of -4.65 and a beta of -0.19.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The firm had revenue of $22.26 million for the quarter, compared to analyst estimates of $11.55 million. As a group, equities research analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.